Barbara Ryan bought $249 of INDV
director at Indivior Pharmaceuticals, Inc.. 8 shares at an average of $31.09, traded Mar 13, 2026, filed Mar 13, 2026.
Score components
- +15RoleDirector
- 0Trade size$249 at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.8%, 3m +23.7%, 6m +10.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001827169-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | POpen-market purchase Common Stock | +8 | $31.09 | $249 | 5,724 | Mar 13, 2026 |
Related signals
Other insiders at Indivior Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | INDVbuy Indivior Pharmaceuticals, Inc. | Woodrow D Anderson Chief Accounting Officer | $54k 1,500 shares | +6% | |
| 25Weak | INDVbuy Indivior Pharmaceuticals, Inc. | Woodrow D Anderson Chief Accounting Officer | $54k 1,500 shares | +6% | |
| 17Weak | Indivior Pharmaceuticals, Inc. | Christian Heidbreder Chief Scientific Officer | $765k 18,586 shares | -8% | |
| 24Weak | Indivior Pharmaceuticals, Inc. | Christian Heidbreder Chief Scientific Officer | $707k 18,586 shares | -8% | |
| 40Moderate | Indivior Pharmaceuticals, Inc. | Ryan Preblick Chief Financial Officer | $1.4M 36,000 shares | -11% | |
| 34Weak | Indivior Pharmaceuticals, Inc. | Stuart A Kingsley director | $30k 940 shares | +20% | |
| 23Weak | Indivior Pharmaceuticals, Inc. | Barbara Ryan director | $1,009 31 shares | +1% | |
| 23Weak | Indivior Pharmaceuticals, Inc. | Keith Humphreys director | $27k 775 shares | +15% | |
| 20Weak | Indivior Pharmaceuticals, Inc. | Daniel A Ninivaggi director | $27k 775 shares | +5% | |
| 20Weak | Indivior Pharmaceuticals, Inc. | Mark Stejbach director | $27k 775 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.